[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1049787B - 採用免疫共軛物和化療劑治療癌症的組合物以及方法 - Google Patents

採用免疫共軛物和化療劑治療癌症的組合物以及方法

Info

Publication number
HK1049787B
HK1049787B HK03100743.7A HK03100743A HK1049787B HK 1049787 B HK1049787 B HK 1049787B HK 03100743 A HK03100743 A HK 03100743A HK 1049787 B HK1049787 B HK 1049787B
Authority
HK
Hong Kong
Prior art keywords
immunoconjugates
compositions
methods
treating cancer
chemotherapeutic agents
Prior art date
Application number
HK03100743.7A
Other languages
English (en)
Other versions
HK1049787A1 (zh
Inventor
V J Chari Ravi
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of HK1049787A1 publication Critical patent/HK1049787A1/zh
Publication of HK1049787B publication Critical patent/HK1049787B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
HK03100743.7A 1999-10-01 2003-01-29 採用免疫共軛物和化療劑治療癌症的組合物以及方法 HK1049787B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15705199P 1999-10-01 1999-10-01
PCT/US2000/026800 WO2001024763A2 (en) 1999-10-01 2000-09-29 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents

Publications (2)

Publication Number Publication Date
HK1049787A1 HK1049787A1 (zh) 2003-05-30
HK1049787B true HK1049787B (zh) 2014-07-25

Family

ID=22562160

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03100743.7A HK1049787B (zh) 1999-10-01 2003-01-29 採用免疫共軛物和化療劑治療癌症的組合物以及方法

Country Status (7)

Country Link
US (3) US7601354B2 (zh)
EP (3) EP2289549A3 (zh)
JP (3) JP4776843B2 (zh)
AU (1) AU775373B2 (zh)
CA (1) CA2385528C (zh)
HK (1) HK1049787B (zh)
WO (1) WO2001024763A2 (zh)

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP2335728A1 (en) 2001-05-11 2011-06-22 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
JP4477303B2 (ja) * 2001-05-16 2010-06-09 ノバルティス アーゲー Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよび化学療法剤を含んでなる併用剤
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
AU2003201824A1 (en) * 2002-01-03 2003-07-24 Smithkline Beecham Corporation Methods for preparing immunoconjugates
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
JP2005532395A (ja) * 2002-07-02 2005-10-27 スミスクライン・ビーチャム・コーポレイション 新規な安定処方
ATE499116T1 (de) * 2002-08-16 2011-03-15 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
WO2004054622A1 (en) 2002-12-13 2004-07-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
CN1816356A (zh) * 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
PL1651162T3 (pl) * 2003-05-20 2016-04-29 Immunogen Inc Maitansynoidy w leczeniu nowotworów
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
KR101581040B1 (ko) 2003-06-27 2015-12-30 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
NO347360B1 (no) * 2003-10-10 2023-09-25 Immunogen Inc Cellebindingsmiddelmaytansinoid-konjugat med formel trastuzumab-SMCC-DM1 eller trastuzumab-SIABDM1, fremgangsmåte for fremstilling av disse og en in vitro fremgangsmåte for å styre maytansinoider til en valgt cellepopulasjon eller for å eliminere celler, samt anvendelse.
US9523231B2 (en) 2003-11-10 2016-12-20 Strattec Power Access Llc Attachment assembly and drive unit having same
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
BRPI0519023A2 (pt) * 2004-12-13 2008-12-23 Hoffmann La Roche composiÇço farmacÊutica contendo pelo menos um derivado de dolastatina 10
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
EP1853322B1 (en) * 2005-02-11 2014-06-25 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
EP1695717A1 (en) * 2005-02-23 2006-08-30 Ludwig-Maximilians-Universität Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
NZ599176A (en) 2005-08-03 2014-04-30 Immunogen Inc Immunoconjugate formulations
CN102989000B (zh) 2005-08-24 2016-04-20 伊缪诺金公司 制备美登木素生物碱抗体缀合物的方法
MX338185B (es) 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
WO2008115404A1 (en) 2007-03-15 2008-09-25 Ludwing Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
TW200918089A (en) 2007-07-16 2009-05-01 Genentech Inc Humanized anti-CD79b antibodies and immunoconjugates and methods of use
CL2008002085A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
CN101896503B (zh) 2007-08-14 2018-05-22 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
AU2009210636B2 (en) 2008-01-31 2014-08-28 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
EP3269366B1 (en) 2008-03-18 2020-01-15 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and lapatinib, and methods of use
MX2010013833A (es) * 2008-06-16 2011-02-15 Immunogen Inc Nuevos efectos sinergisticos.
HUE060624T2 (hu) 2009-02-13 2023-04-28 Immunomedics Inc Sejten belüli hasítható kötést tartalmazó immunkonjugátumok
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
CN102573916B (zh) 2009-05-06 2017-05-17 生物测试股份公司 靶向cd138的免疫偶联物的应用
EP2437790B1 (en) 2009-06-03 2019-02-20 Immunogen, Inc. Conjugation methods
PL2437785T3 (pl) 2009-06-04 2015-08-31 Novartis Ag Sposoby identyfikacji miejsc sprzęgania IgG
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
MX2012004406A (es) * 2009-10-21 2012-05-08 Immunogen Inc Nuevo regimen de dosificacion y metodo de tratamiento.
RU2016105962A (ru) 2009-12-04 2018-11-23 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
BR112012017642A2 (pt) * 2010-01-21 2016-04-12 Immunogen Inc composições e métodos para tratamento de câncer de ovário
EP2533810B1 (en) 2010-02-10 2016-10-12 ImmunoGen, Inc. Cd20 antibodies and uses thereof
MA34057B1 (fr) 2010-02-23 2013-03-05 Genentech Inc Compositions et methodes pour le diagnostic et le traitement d'une tumeur
AU2011226672B2 (en) 2010-03-12 2015-07-23 Immunogen, Inc. CD37-binding molecules and immunoconjugates thereof
ES2905690T3 (es) 2010-04-15 2022-04-11 Kodiak Sciences Inc Polímeros que contienen zwitteriones de alto peso molecular
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
WO2012016227A2 (en) 2010-07-29 2012-02-02 Xencor, Inc. Antibodies with modified isoelectric points
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
EP2632490A4 (en) 2010-10-29 2014-10-22 Immunogen Inc NOVEL MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012097333A2 (en) 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
KR102272828B1 (ko) 2011-03-29 2021-07-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
US9447189B2 (en) 2011-04-01 2016-09-20 Immunogen, Inc. CD37-binding molecules and immunoconjugates thereof
DK2717916T3 (en) 2011-06-10 2017-04-24 Mersana Therapeutics Inc PROTEIN POLYMER-drug conjugates
WO2012177837A2 (en) * 2011-06-21 2012-12-27 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
AU2015224535B2 (en) * 2011-06-21 2017-07-20 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
AU2012323287B2 (en) 2011-10-10 2018-02-01 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9233171B2 (en) 2011-11-21 2016-01-12 Immunogen, Inc. Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate
KR20140100571A (ko) 2011-12-08 2014-08-14 바이오테스트 아게 Ｃｄ１３８을 타겟팅하는 면역접합체의 용도
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
BR112014027166A2 (pt) 2012-05-01 2017-06-27 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção.
BR112014028366A2 (pt) 2012-05-21 2017-06-27 Genentech Inc anticorpos anti-ly6e e imunoconjugados e métodos de uso
KR20150039818A (ko) 2012-08-02 2015-04-13 제넨테크, 인크. 항-etbr 항체 및 면역접합체
EP2879711A4 (en) 2012-08-02 2016-03-16 Genentech Inc ANTI-ETBR ANTIBODIES AND IMMUNOCONJUGATES
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
NZ739573A (en) 2012-09-26 2019-11-29 Immunogen Inc Improved methods for the acylation of maytansinol
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014093394A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2931316B1 (en) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
KR20230078823A (ko) 2012-12-13 2023-06-02 이뮤노메딕스, 인코오포레이티드 개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
CN105051069B (zh) 2013-01-14 2019-12-10 Xencor股份有限公司 新型异二聚体蛋白
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
AU2014232501C1 (en) 2013-03-15 2021-04-22 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP2994164B1 (en) 2013-05-08 2020-08-05 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN105518027A (zh) 2013-09-17 2016-04-20 豪夫迈·罗氏有限公司 使用抗lgr5抗体的方法
RU2016117810A (ru) 2013-10-11 2017-11-17 Асана Биосайенсис, Ллк Конъюгаты белок-полимер-лекарственное средство
PE20160561A1 (es) 2013-10-11 2016-06-03 Oxford Biotherapeutics Ltd Anticuerpos conjugados contra ly75 para el tratamiento de cancer
CN105979970B (zh) 2013-10-11 2019-09-10 梅尔莎纳医疗公司 蛋白质-聚合物-药物共轭物
AR098126A1 (es) 2013-10-21 2016-05-04 Genentech Inc Anticuerpos anti-ly6e (locus e del complejo del antígeno 6 linfocítico), inmunoconjugados y métodos para usarlos
EP3068892A4 (en) 2013-11-13 2017-05-31 Zymeworks Inc. Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
UA119167C2 (uk) 2014-03-28 2019-05-10 Зенкор, Інк. Біспецифічне антитіло, яке зв'язується з cd38 та cd3
CA2956178A1 (en) 2014-07-24 2016-01-28 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
AU2015314826A1 (en) 2014-09-12 2017-03-02 Genentech, Inc. Cysteine engineered antibodies and conjugates
ES2796903T3 (es) 2014-09-23 2020-11-30 Hoffmann La Roche Procedimiento de uso de inmunoconjugados anti-CD79b
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
HUE055115T2 (hu) 2014-11-26 2021-10-28 Xencor Inc CD3-at és CD20-at kötõ heterodimer antitestek
SG11201704274QA (en) 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
EP3226910A1 (en) 2014-12-04 2017-10-11 Celgene Corporation Biomolecule conjugates
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
WO2016200676A1 (en) 2015-06-08 2016-12-15 Immunogen, Inc. Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
EP3341414A4 (en) 2015-08-28 2019-03-27 Debiopharm International SA ANTIBODIES AND ASSAYS FOR DETECTION OF CD37
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
CN108601841A (zh) 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
JP2019515677A (ja) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法
CA3016917A1 (en) 2016-04-27 2017-11-02 Immunomedics, Inc. Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
EP4257613A3 (en) 2016-06-14 2023-12-13 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
EP3474901A1 (en) 2016-06-27 2019-05-01 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
CN109715663B (zh) 2016-06-28 2022-11-25 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG11201903302UA (en) 2016-10-14 2019-05-30 Xencor Inc Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
EP3535297B1 (en) 2016-11-02 2022-08-10 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
EP3600283A4 (en) 2017-03-27 2020-12-16 Immunomedics, Inc. TREATMENT OF TROP-2 EXPRESSIVE TRIPLE NEGATIVE BREAST CANCER WITH SACITUZUMAB GOVITECAN AND A RAD51 INHIBITOR
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CA3066754A1 (en) 2017-06-22 2018-12-27 Mersana Therapeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
CN107488231B (zh) * 2017-09-15 2020-10-30 四川大学 抗cd56抗体及其用途
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
CN111655718A (zh) 2017-12-19 2020-09-11 Xencor股份有限公司 经过工程化的il-2 fc融合蛋白
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
MX2020010910A (es) 2018-04-18 2021-02-09 Xencor Inc Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
AU2019262521B2 (en) 2018-05-04 2024-04-18 Tagworks Pharmaceuticals B.V. Compounds comprising a linker for increasing transcyclooctene stability
US20210299286A1 (en) 2018-05-04 2021-09-30 Tagworks Pharmaceuticals B.V. Tetrazines for high click conjugation yield in vivo and high click release yield
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
KR20210028204A (ko) 2018-07-02 2021-03-11 암젠 인크 항-steap1 항원 결합 단백질
MA53822A (fr) 2018-10-03 2021-08-11 Xencor Inc Protéines de fusion fc hétérodimères d'il -12
KR20210084546A (ko) 2018-10-29 2021-07-07 메르사나 테라퓨틱스, 인코포레이티드 펩티드 함유 링커를 갖는 시스테인 조작된 항체-약물 접합체
CA3121902A1 (en) 2018-12-04 2020-06-11 Der-Yang Tien Stereocomplexes for the delivery of anti-cancer agents
CA3132185A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
EP3983363B1 (en) 2019-06-17 2024-04-10 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
US20210402001A1 (en) * 2020-06-30 2021-12-30 David I. Cohen Zinc Porters, and their Monoclonal Antibody Conjugates, for the Prevention and Treatment of COVID-19 (SARS-CoV-2), Other Infections, and Cancers
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc ANTI–CD28 COMPOSITIONS
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
CN118339280A (zh) 2021-09-06 2024-07-12 维拉克萨生物技术有限责任公司 用于真核生物中遗传密码子扩展的新型氨酰tRNA合成酶变体
EP4433170A1 (en) 2021-11-18 2024-09-25 Oxford BioTherapeutics Ltd Pharmaceutical combinations
KR20240105469A (ko) 2021-11-25 2024-07-05 베락사 바이오테크 게엠베하 유전자 코드 확장을 이용하는 부위-특이적 접합에 의해 제조되는 개선된 항체-페이로드 접합체 (apc)
EP4186529A1 (en) 2021-11-25 2023-05-31 Veraxa Biotech GmbH Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
AU2022404647A1 (en) 2021-12-08 2024-06-13 European Molecular Biology Laboratory Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
WO2023158305A1 (en) 2022-02-15 2023-08-24 Tagworks Pharmaceuticals B.V. Masked il12 protein
WO2024013723A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2024080872A1 (en) 2022-10-12 2024-04-18 Tagworks Pharmaceuticals B.V. Strained bicyclononenes
WO2024153789A1 (en) 2023-01-20 2024-07-25 Basf Se Stabilized biopolymer composition, their manufacture and use
WO2024191293A1 (en) 2023-03-10 2024-09-19 Tagworks Pharmaceuticals B.V. Trans-cyclooctene with improved t-linker

Family Cites Families (785)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US506333A (en) 1893-10-10 norwell
US171217A (en) 1875-12-21 Improvement in convertible revolving harrows
NL6613143A (zh) 1965-09-21 1967-03-22
US4177263A (en) 1972-02-28 1979-12-04 Research Corporation Anti-animal tumor method
US5562925A (en) 1970-04-20 1996-10-08 Research Corporation Tech. Inc. Anti-tumor method
CH588505A5 (zh) 1972-06-08 1977-06-15 Research Corp
US3870719A (en) 1972-06-16 1975-03-11 Us Health Synthesis of n-5-methyltetrahydrohomofolic acid and related reduced derivatives of homofolic acid
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4479957A (en) 1973-04-02 1984-10-30 Eli Lilly And Company Use of vindesine in treating acute lymphatic leukemia and _other susceptible neoplasms
US3965254A (en) 1973-05-23 1976-06-22 The Procter & Gamble Company Compositions for the treatment of calcific tumors
US3932417A (en) 1973-10-24 1976-01-13 Eli Lilly And Company Dimeric indole alkaloid purification process
US3887565A (en) 1974-05-06 1975-06-03 Lilly Co Eli Vincadioline
US4207416A (en) 1974-09-05 1980-06-10 Engelhard Minerals & Chemicals Corporation Ethylenediamineplatinum(II) 2,4-dioxopyrimidine complexes
US3954773A (en) 1974-11-21 1976-05-04 Eli Lilly And Company 4-Desacetoxyvinblastine
US4079121A (en) 1974-12-13 1978-03-14 Mobil Oil Corporation Complexes of beta platinum chloride and ammonia
FR2296418B1 (zh) 1974-12-30 1978-07-21 Anvar
US3944554A (en) 1975-01-09 1976-03-16 Eli Lilly And Company 4-Desacetoxy-3-hydroxyvinblastine
JPS5198300A (en) 1975-02-20 1976-08-30 Kanputoteshin oyobi sonoruijitaino seizoho
US4279817A (en) 1975-05-30 1981-07-21 The United States Of America As Represented By The Department Of Health & Human Services Method for producing dimer alkaloids
US4029663A (en) 1975-07-10 1977-06-14 Eli Lilly And Company Dimeric anhydro-vinca derivatives
HU172708B (hu) 1975-10-28 1978-11-28 Richter Gedeon Vegyeszet Novyj sposob razdelenija diindolil-alkaloidov
US4255417A (en) 1976-08-04 1981-03-10 Johnson Matthey, Inc. Platinum compounds for the irradication of skin blemishes
US4115418A (en) 1976-09-02 1978-09-19 Government Of The United States Of America 1,2-diaminocyclohexane platinum (ii) complexes having antineoplastic activity
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
USRE30560E (en) 1976-12-06 1981-03-31 Eli Lilly And Company Oxazolidinedione derivatives of Vinca alkaloids
US4096148A (en) 1976-12-06 1978-06-20 Eli Lilly And Company Oxazolidinedione derivatives of Vinca alkaloids
USRE30561E (en) 1976-12-06 1981-03-31 Eli Lilly And Company Vinca alkaloid intermediates
US4160767A (en) 1976-12-06 1979-07-10 Eli Lilly And Company Vinca alkaloid intermediates
US4175133A (en) 1977-02-18 1979-11-20 United States Of America 1,2-Diaminocyclohexane platinum (II) complexes having antineoplastic activity against L1210 leukemia
US4162940A (en) 1977-03-31 1979-07-31 Takeda Chemical Industries, Ltd. Method for producing Antibiotic C-15003 by culturing nocardia
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4278660A (en) 1977-05-02 1981-07-14 Research Corporation Complex or salt of a platinum (II) compound and a nitrogen containing polymer
US4151185A (en) 1977-05-02 1979-04-24 Research Corporation Complex or salt of a platinum (II) compound and a nitrogen containing polymer
HU178084B (en) 1977-05-31 1982-03-28 Richter Gedeon Vegyeszet New process for the extraction of native vindoline,catharantine,3',4'-anhydrovinblastine,leurosine and,if desired,of other diinodle alkaloids from vinca rosea l.drogue
US4260609A (en) 1977-06-01 1981-04-07 Merck & Co., Inc. Di- and tri- substituted thiazoles
US4419351A (en) 1977-06-03 1983-12-06 Research Corporation Platinum-dioxopyrimidine complexes
US4137248A (en) 1977-08-29 1979-01-30 The United States Of America As Represented By The Department Of Health, Education And Welfare Compound, 4-carboxyphthalato(1,2-diaminocyclohexane)-platinum(II) and alkali metal salts thereof
JPS5829957B2 (ja) 1977-09-12 1983-06-25 喜徳 喜谷 新規な白金錯体
US4203912A (en) 1977-10-19 1980-05-20 Johnson, Matthey & Co., Limited Compositions containing platinum
US4225529A (en) 1977-10-19 1980-09-30 Johnson, Matthey & Co., Limited Compositions containing platinum
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4159269A (en) 1978-03-03 1979-06-26 Eli Lilly And Company Preparation of oxazolidinedione derivatives of Vinca alkaloids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
EP0004770B1 (en) 1978-04-11 1984-06-13 Efamol Limited Pharmaceutical and dietary composition comprising gamma-linolenic acids
SE7903361L (sv) 1978-04-20 1979-10-21 Johnson Matthey Co Ltd Kompositioner innehallande platina
US4199504A (en) 1978-05-15 1980-04-22 Eli Lilly And Company Bridged cathranthus alkaloid dimers
US4208414A (en) 1978-06-05 1980-06-17 Eli Lilly And Company Vinblastine in rheumatoid arthritis
JPS6034958B2 (ja) 1978-09-02 1985-08-12 喜徳 喜谷 新規白金錯体
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
US4234500A (en) 1979-03-07 1980-11-18 Engelhard Minerals & Chemicals Corporation Ethylenediamine platinum(II) and 1,2-diamino-cyclohexane platinum(II) pyrophosphate complexes
US4287187A (en) 1979-03-07 1981-09-01 Engelhard Minerals & Chemicals Corporation Method for treating tumors with cis-diammineplatinum(II) orthophosphate complexes
US4291023A (en) 1979-03-07 1981-09-22 Engelhard Minerals & Chemicals Corp. Method for treating tumors using cis-diammineplatinum (II) organophosphate complexes
US4234499A (en) 1979-03-07 1980-11-18 Engelhard Minerals & Chemicals Corporation Cis-diammireplatinum(II) organophosphate complexes
US4248840A (en) 1979-03-07 1981-02-03 Engelhard Minerals And Chemicals Corporation Cis-diammineplatinum(II) orthophosphate complexes
US4291027A (en) 1979-03-07 1981-09-22 Engelhard Minerals & Chemicals Corp. Method for treating tumors with ethylenediamine platinum (II) and 1,2-diaminocyclohexane-platinum (II) pyrophosphate complexes
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4462998A (en) 1979-06-20 1984-07-31 Engelhard Corporation Method of using a cis-platinum(II) amine ascorbate
US4457926A (en) 1979-06-20 1984-07-03 Engelhard Corporation Cis-Platinum(II) amine ascorbate complexes
US4271085A (en) 1979-06-20 1981-06-02 Engelhard Minerals & Chemicals Corporation Cis-platinum (II) amine lactate complexes
US4399282A (en) 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4284579A (en) 1979-07-17 1981-08-18 The United States Of America As Represented By The Of The Department Of Health & Human Services (N-Phosphonacetyl-L-aspartato)(1,2-diaminocyclchexane)platinum(II) or alkali metal salt
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
US4335087A (en) 1979-08-16 1982-06-15 Mpd Technology Corporation Process for preparing cis-Pt(NH3)2 Cl2
US4273755A (en) 1979-08-16 1981-06-16 Mpd Technology Corporation Preparation of platinum complexes
US4329299A (en) 1979-08-23 1982-05-11 Johnson, Matthey & Co., Limited Composition of matter containing platinum
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
US4302446A (en) 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
NL181434C (nl) 1980-01-03 1987-08-17 Tno Platina(iv)-diamine-complexen, alsmede hun bereiding en toepassing.
US4325950A (en) 1980-02-19 1982-04-20 The Research Corporation Of The University Of Hawaii Platinum caffeine chloride anion complex and method
US4428943A (en) 1980-06-09 1984-01-31 The United States Of America As Represented By The Department Of Health And Human Services (N-Phosphonacetyl-L-aspartato) (1,2-diaminocyclohexane)platinum(II) or alkali metal salt
US4407300A (en) 1980-07-14 1983-10-04 Davis Robert E Potentiometric diagnosis of cancer in vivo
US4581224A (en) 1980-08-08 1986-04-08 Regents Of The University Of Minnesota Inhibition of undesired effect of platinum compounds
US4594238A (en) 1980-08-08 1986-06-10 Regents Of University Of Minnesota Inhibition of undesired effect of platinum compounds
IL63658A0 (en) 1980-09-03 1981-11-30 Johnson Matthey Plc Co-ordination compound of platinum and its preparation
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
HU183234B (en) 1980-10-17 1984-04-28 Richter Gedeon Vegyeszet Process for the enantioselective synthesis of optically active cys-14-oxo-e-homo-eburnan
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS57123198A (en) 1981-01-23 1982-07-31 Shionogi & Co Ltd Novel platinum complex
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
NL8101026A (nl) 1981-03-03 1982-10-01 Tno Platinadiamine-complexen, werkwijze voor het bereiden daarvan, werkwijze voor het bereiden van een geneesmiddel met toepassing van een dergelijk platinadiamine-complex voor de behandeling van kanker alsmede aldus verkregen gevormd geneesmiddel.
DE3269549D1 (en) 1981-04-02 1986-04-10 Atomic Energy Authority Uk Improvements in or relating to the production of chemical compounds
US4375432A (en) 1981-05-12 1983-03-01 Eli Lilly And Company Method of preparing vincristine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4515954A (en) 1981-08-24 1985-05-07 American Cyanamid Company Metal chelates of anthracene-9,10-bis-carbonylhydrazones
US4414205A (en) 1981-08-28 1983-11-08 University Patents, Inc. Cell growth inhibitory substances
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS5839685A (ja) 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
US5108987A (en) 1982-02-25 1992-04-28 Faulk Ward P Conjugates of proteins with anti-tumor agents
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS58167592A (ja) 1982-03-26 1983-10-03 Takeda Chem Ind Ltd 新規メイタンシノイド化合物
US5087618A (en) 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
LU84664A1 (fr) 1983-02-25 1984-11-08 Onmichem S A Alkyl-4-indolonaphtyridines et leur application therapeutique
US4476026A (en) 1983-03-21 1984-10-09 The Perkin-Elmer Corporation Apparatus useful in identifying a solute
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
USRE33071E (en) 1983-03-28 1989-09-26 Platinum bound to transferrin for use in the treatment of breast tumors
US4906646A (en) 1983-03-31 1990-03-06 Board Of Governors Of Wayne State University Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class
US4720504A (en) 1983-05-10 1988-01-19 Andrulis Research Corporation Use of bis-platinum complexes as antitumor agents
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
CA1237670A (en) 1983-05-26 1988-06-07 Andrew S. Janoff Drug preparations of reduced toxicity
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4544759A (en) 1983-07-29 1985-10-01 American Cyanamid Company Platinum complexes of antitumor agents
JPS6032799A (ja) 1983-07-29 1985-02-19 Microbial Chem Res Found 新規４′−デメチル−４−エピポドフィロトキシン誘導体
US4550169A (en) 1983-11-21 1985-10-29 American Cyanamid Company Platinum chelates of 2-hydrazino-azoles
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
US4522750A (en) 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
US4599352A (en) 1984-03-01 1986-07-08 The United States Of America As Represented By The Department Of Health And Human Services Antineoplastic platinum (IV) complexes and compositions
US4562275A (en) 1984-03-23 1985-12-31 Bristol-Myers Co. Antitumor platinum complexes
US4593034A (en) 1984-04-06 1986-06-03 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides
US4843161A (en) 1984-06-01 1989-06-27 Massachusetts Institute Of Technology Platinum-intercalative complexes for the treatment of cancer
GB8416048D0 (en) 1984-06-22 1984-07-25 Johnson Matthey Plc Anti-tumour compounds of platinum
DE3582961D1 (de) 1984-06-27 1991-07-04 Johnson Matthey Plc Platinkoordinationsverbindungen.
EP0169645A1 (en) 1984-06-27 1986-01-29 Johnson Matthey Public Limited Company Platinum co-ordination compounds
US4952676A (en) 1984-06-27 1990-08-28 Johnson Matthey Plc Monoclonal antibody-platinum co-ordination compound complex
US4956454A (en) 1984-06-27 1990-09-11 Johnson Matthey Plc Monoclonal antibody - platinum co-ordination compound complex
US4645661A (en) 1984-06-29 1987-02-24 St. Jude Children's Research Hospital Method for alleviating cisplatin-induced nephrotoxicity and dithiocarbamate compounds for effecting same
US4767611A (en) 1984-07-03 1988-08-30 Gordon Robert T Method for affecting intracellular and extracellular electric and magnetic dipoles
HU193809B (en) 1984-09-12 1987-12-28 Chugai Pharmaceutical Co Ltd Process for producing new platinum complexes
US4665210A (en) 1984-12-17 1987-05-12 American Cyanamid Company Platinum complexes of aliphatic tricarboxylic acids
US4587331A (en) 1984-12-17 1986-05-06 American Cyanamid Company Platinum complexes of polyhydroxylated alkylamines and 2-polyhydroxylated alkyl-1,2-diaminoethanes
US4739087A (en) 1985-01-10 1988-04-19 Bristol-Myers Company Antineoplastic platinum complexes
JPS61227590A (ja) 1985-04-02 1986-10-09 Microbial Chem Res Found 新規４′−デメチル−４−エピポドフイロトキシン誘導体
US5086182A (en) 1985-04-12 1992-02-04 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
US4728740A (en) 1985-04-12 1988-03-01 Bristol-Myers Company Intermediates for the production of epipodophylotoxin and related compounds and processes for the preparation and use thereof
US4866189A (en) 1985-04-12 1989-09-12 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
US5120862A (en) 1985-04-12 1992-06-09 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
US4644072A (en) 1985-04-12 1987-02-17 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
US4795819A (en) 1985-04-12 1989-01-03 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
US5011948A (en) 1985-04-12 1991-04-30 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
US4686104A (en) 1985-04-30 1987-08-11 Sloan-Kettering Institute For Cancer Research Methods of treating bone disorders
US4895727A (en) 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4667030A (en) 1985-06-17 1987-05-19 Eli Lilly And Company Hydrazide succinimide derivatives of antineoplastic indole-dihydroindole alkaloids
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
JPH0665648B2 (ja) 1985-09-25 1994-08-24 塩野義製薬株式会社 白金系抗癌物質の安定な凍結真空乾燥製剤
US5041581A (en) 1985-10-18 1991-08-20 The University Of Texas System Board Of Regents Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5117022A (en) 1985-10-18 1992-05-26 The Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
GB8525689D0 (en) 1985-10-18 1985-11-20 Johnson Mathey Plc Platinum coordination compounds
US5384127A (en) 1985-10-18 1995-01-24 Board Of Regents, The University Of Texas System Stable liposomal formulations of lipophilic platinum compounds
CA1275922C (en) 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
EP0232693A3 (fr) 1985-12-16 1988-04-06 La Region Wallonne Conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques les contenant
IL77334A (en) 1985-12-16 1991-04-15 Univ Bar Ilan Synthesis of 9-epipodophyllotoxin glucoside derivatives and some novel intermediates therefor
LU86212A1 (fr) 1985-12-16 1987-07-24 Omnichem Sa Nouveaux conjugues de la vinblastine et de ses derives,procede pour leur preparation et compositions pharmaceutiques les contenant
US4970324A (en) 1985-12-24 1990-11-13 Hoeschele James D Aminoalkyl-substituted azetidine platinum(II) complexes
US5116831A (en) 1985-12-24 1992-05-26 Warner-Lambert Company Aminoalkyl-substituted cycloalkylamine platinum (II) complexes
JPH075608B2 (ja) 1986-01-13 1995-01-25 イ−ル−セルタ−ク ソシエテ アノニム ビンブラスチン誘導体
IL81264A (en) 1986-01-30 1990-11-05 Takeda Chemical Industries Ltd Quinone derivatives,their production and pharmaceutical compositions containing them
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5395924A (en) 1986-03-20 1995-03-07 Dana-Farber Cancer Institute, Inc. Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4765972A (en) 1986-04-03 1988-08-23 The United States Of America As Represented By The Department Of Health And Human Services Vinca alkaloid photoactive analogs and their uses
US5078137A (en) 1986-05-05 1992-01-07 Massachusetts Institute Of Technology Apparatus for measuring oxygen partial pressure and temperature, in living tissue
US5100877A (en) 1986-05-21 1992-03-31 Kuraray Co., Ltd. Platinum containing pullulan derivatives and pharmaceutical compositions comprising the same
US4801688A (en) 1986-05-27 1989-01-31 Eli Lilly And Company Hydrazone immunoglobulin conjugates
US5182368A (en) 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
GB8620917D0 (en) 1986-08-29 1986-10-08 Davidson B C Platinum derivatives & cancer treatments
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
ES2016313B3 (es) 1986-10-03 1990-11-01 Asta Pharma Ag Compuestos de complejos diamina-platino (ii) con un anillo fenil-indol hidroxilado.
PH23232A (en) 1986-10-07 1989-06-06 Boehringer Biochemia Robin Pharmaceutical compositions having antineoplastic activity
US4906755A (en) 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5011959A (en) 1986-11-17 1991-04-30 The Board Of Regents, The University Of Texas System 1,2-diaminocyclohexane-platinum complexes with antitumor activity
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US4916217A (en) 1987-01-08 1990-04-10 Bristol-Myers Company Phosphorus containing derivatives of epipodophyllotoxin
US5047528A (en) 1987-01-22 1991-09-10 University Of Bristish Columbia Process of synthesis of vinblastine and vincristine
US5057302A (en) 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
US5256653A (en) 1987-02-19 1993-10-26 Henkel Kommanditgesellschaft Auf Aktien Pharmaceutical preparations containing platinum complexes/phosphonic acid liquid and processes for their use
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5079600A (en) 1987-03-06 1992-01-07 Schnur Joel M High resolution patterning on solid substrates
CA1283904C (en) 1987-03-06 1991-05-07 Mitsuaki Maeda Liposoluble platinum (ii) complex and preparation thereof
US5053512A (en) 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5106742A (en) 1987-03-31 1992-04-21 Wall Monroe E Camptothecin analogs as potent inhibitors of topoisomerase I
US5364858A (en) 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5244903A (en) 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5122526A (en) 1987-03-31 1992-06-16 Research Triangle Institute Camptothecin and analogs thereof and pharmaceutical compositions and method using them
US5227380A (en) 1987-03-31 1993-07-13 Research Triangle Institute Pharmaceutical compositions and methods employing camptothecins
US4894456A (en) 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US4921963A (en) 1987-04-13 1990-05-01 British Columbia Cancer Foundation Platinum complexes with one radiosensitizing ligand
US5026694A (en) 1987-04-13 1991-06-25 The British Columbia Cancer Foundation Platinum complexes with one radiosensitizing ligand
US5340817A (en) 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
US5049668A (en) 1989-09-15 1991-09-17 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin analogs
US5180722A (en) 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
US5122606A (en) 1987-04-14 1992-06-16 Research Triangle Institute 10,11-methylenedioxy camptothecins
DK252688A (da) 1987-05-08 1988-11-09 Sankyo Co Antitumorplatinkomplekser, fremgangsmaade til fremstilling deraf, samt deres terapeutiske anvendelse
US5811119A (en) 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US4853467A (en) 1987-05-19 1989-08-01 Bristol-Myers Company Nitrogen containing derivatives of epipodophyllotoxin glucosides
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4927966A (en) 1987-06-04 1990-05-22 The Research Foundation Of State University Of New York 2-mercaptomethylglutaric acid derivatives
US5010103A (en) 1987-06-04 1991-04-23 The Research Foundation Of State University Of N.Y. Compositions and methods comprising 2-mercaptomethylglutaric acid derivatives
US4939255A (en) 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
CA1332413C (en) 1987-06-25 1994-10-11 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US4874851A (en) 1987-07-01 1989-10-17 Bristol-Meyers Company 3',4'-dinitrogen substituted epipodophyllotoxin glucoside derivatives
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5053226A (en) 1987-07-15 1991-10-01 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
US4956459A (en) 1987-07-17 1990-09-11 Georgetown University Platinum compounds suitable for use as pharmaceuticals
US4895935A (en) 1987-07-17 1990-01-23 Georgetown University Platinum pharmaceuticals
US4895936A (en) 1987-07-17 1990-01-23 Georgetown University Platinum pharmaceuticals
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
ZA885929B (en) 1987-08-25 1989-04-26 Oxi Gene Inc Agents for use in tumor or cancer cell killing therapy
US4888419A (en) 1987-08-31 1989-12-19 Bristol-Myers Company 3'-demethoxyepipodophyllotoxin glucoside derivatives
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US4943579A (en) 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
FR2623504B1 (fr) 1987-11-25 1990-03-09 Adir Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
US4936465A (en) 1987-12-07 1990-06-26 Zoeld Tibor Method and apparatus for fast, reliable, and environmentally safe dispensing of fluids, gases and individual particles of a suspension through pressure control at well defined parts of a closed flow-through system
US5378803A (en) 1987-12-11 1995-01-03 Sterling Winthrop Inc. Azole-fused peptides and processes for preparation thereof
US4935504A (en) 1987-12-18 1990-06-19 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-acyl derivatives
US5292497A (en) 1987-12-22 1994-03-08 U.S. Bioscience, Inc. Method of reducing chemotherapy toxicity using (methylaminopropylamino)propyl dihydrogen phosphorothioate
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
JPH0615547B2 (ja) 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
US4958010A (en) 1988-02-16 1990-09-18 Bristol-Myers Company Epipodophyllotoxin glucoside lactam derivatives
US5002755A (en) 1988-02-18 1991-03-26 Vanderbilt University Method of controlling nephrotoxicity of anti-tumor plaintum compounds
US5011846A (en) 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
GB8806224D0 (en) 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
NO169490C (no) 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
USRE34277E (en) 1988-04-06 1993-06-08 Centre National De La Recherche Scientifique Process for preparing taxol
FR2629818B1 (fr) 1988-04-06 1990-11-16 Centre Nat Rech Scient Procede de preparation du taxol
FR2629819B1 (fr) 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US4923876A (en) 1988-04-18 1990-05-08 Cetus Corporation Vinca alkaloid pharmaceutical compositions
GB8810173D0 (en) 1988-04-29 1988-06-02 Norsk Hydro As Pharmaceutical compositions with anti-cancer activity & method for treatment of cancer
AU641361B2 (en) 1988-05-02 1993-09-23 Zynaxis Technologies, Incorporated Compounds, compositions and method for binding bio-affecting substances to surface membranes of bio-particles
US4931553A (en) 1988-05-11 1990-06-05 Gill Devinder S Platinum-polymer complexes and their use as antitumor agents
US4952408A (en) 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US4946835A (en) 1988-07-15 1990-08-07 Merck & Co., Inc. Antifungal fermentation product and method
US5084002A (en) 1988-08-04 1992-01-28 Omnitron International, Inc. Ultra-thin high dose iridium source for remote afterloader
DE3827974A1 (de) 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US4912204A (en) 1988-09-06 1990-03-27 Bristol-Myers Company Fluoro-substituted epipodophyllotoxin glucosides
US5705334A (en) 1988-09-22 1998-01-06 Massachusetts Institute Of Technology Uses for DNA structure-specific recognition protein
US5359047A (en) 1988-09-22 1994-10-25 Massachusetts Institute Of Technology Nucleic acids encoding DNA structure-specific recognition protein and uses therefor
US5213788A (en) 1988-09-29 1993-05-25 Ranney David F Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
US4912072A (en) 1988-10-21 1990-03-27 Gas Research Institute Method for selective internal platinization of porous aluminosilicates
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5393909A (en) 1988-11-22 1995-02-28 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
US5041578A (en) 1988-11-22 1991-08-20 Board Of Regents, The University Of Texas System Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
US5434256A (en) 1988-11-22 1995-07-18 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
US5612019A (en) 1988-12-19 1997-03-18 Gordon, Deceased; David Diagnosis and treatment of HIV viral infection using magnetic metal transferrin particles
US5242824A (en) 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
US5217713A (en) 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4946954A (en) 1989-01-17 1990-08-07 Georgetown University Platinum pharmaceutical agents
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
WO1990008768A1 (en) 1989-02-01 1990-08-09 Institut Fizicheskoi Khimii Imeni L.V.Pisarzhevskogo Akademii Nauk Ukrainskoi Ssr Derivatives of platinum (p) with methyl silicone, method of obtaining them and antitumoral means based thereon
US5676978A (en) 1989-02-14 1997-10-14 Amira, Inc. Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
US5300500A (en) 1989-02-23 1994-04-05 The University Of North Carolina At Chapel Hill 4 beta-amino podophyllotoxin analog compounds and methods
US4985416A (en) 1989-03-13 1991-01-15 Dana Farber Cancer Institute, Inc. Platinum complexes of azodiazonium dyes as anti-tumor agents
US5019504A (en) 1989-03-23 1991-05-28 The United States Of America As Represented By The Secretary Of Agriculture Production of taxol or taxol-like compounds in cell culture
US5004593A (en) 1989-04-17 1991-04-02 Mayo Foundation For Medical Education And Research Hexamethylmelamine formulation exhibiting reduced neurotoxicity
IT1230145B (it) 1989-05-05 1991-10-14 Boehringer Biochemia Srl Complessi di rutenio (iii) come agenti antineoplastici.
US5162115A (en) 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US4965348A (en) 1989-05-19 1990-10-23 Bristol-Myers Company Dimeric epipodophyllotoxin glucoside derivatives
MY110249A (en) 1989-05-31 1998-03-31 Univ Florida State Method for preparation of taxol using beta lactam
US5175315A (en) 1989-05-31 1992-12-29 Florida State University Method for preparation of taxol using β-lactam
US4994591A (en) 1989-06-02 1991-02-19 The Research Foundation Of State University Of Ny Platinum complexes derived from b-silyamines
US5036055A (en) 1989-06-07 1991-07-30 Bristol-Myers Company Acylated derivatives of etoposide
GB8914040D0 (en) 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5208238A (en) 1989-06-19 1993-05-04 Burroughs Wellcome Company Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
GB8914060D0 (en) 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914061D0 (en) 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
FR2651348B1 (zh) 1989-08-04 1993-01-22 Adir
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
US5066645A (en) 1989-09-01 1991-11-19 Bristol-Myers Company Epipodophyllotoxin altroside derivatives
DE69033880T2 (de) 1989-09-15 2002-06-06 Research Triangle Institute, Research Triangle Park Verfahren zur herstellung von 10,11-Methylendioxy-20(RS)-Camptothecin und 10,11-Methylendioxy-20(S)-Camptothecin-Analog
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
HU204995B (en) 1989-11-07 1992-03-30 Richter Gedeon Vegyeszet Process for producing pharmaceutical composition comprising alkaloid with bis-indole skeleton, with antitumour activity and suitable fr parenteral purposes
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5136060A (en) 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
US5015744A (en) 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
US5034380A (en) 1989-11-20 1991-07-23 Bristol-Myers Squibb Company Alkoxymethylidene epipodophyllotoxin glucosides
US5258376A (en) 1989-11-22 1993-11-02 Bernstein Lawrence R Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
ATE143967T1 (de) 1989-12-12 1996-10-15 Toray Industries Neuer platin(ii)komplex und mittel für die behandlung von bösartigen tumoren
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
KR910014122A (ko) 1990-01-19 1991-08-31 디께다 가즈히꼬 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
US5028726A (en) 1990-02-07 1991-07-02 The University Of Vermont And State Agricultural College Platinum amine sulfoxide complexes
WO1991015124A1 (en) 1990-04-10 1991-10-17 The University Of Vermont Modulator agent and use thereof
US5238955A (en) 1990-04-10 1993-08-24 Asta Pharma Ag Ethylene-substituted phenylalkylethylenediamine-platinum (II or IV) derivatives and phenylalkylethylenediamines
US5081234A (en) 1990-04-30 1992-01-14 Bristol-Myers Squibb Co. 4'-demethylepipodophyllotoxin glycosides
FR2662440B1 (fr) 1990-05-22 1992-07-31 Rhone Poulenc Sante Procede de preparation stereoselective de derives de la phenylisoserine.
US4997931A (en) 1990-06-11 1991-03-05 Bristol-Myers Squibb Company Epipodophyllotoxin glycosides
GB9017024D0 (en) 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
US5091368A (en) 1990-08-08 1992-02-25 Harbor Branch Oceanographic Institution, Inc. Biologically active compounds from blue-green algae
ATE186461T1 (de) 1990-09-28 1999-11-15 Smithkline Beecham Corp Verfahren zur herstellung wasserlöslicher camptothecinanaloge, sowie die verbindungen 10- hydroxy-11-c(1-6)-alkoxycamptothecin
US5147294A (en) 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
US5475120A (en) 1990-11-02 1995-12-12 University Of Florida Method for the isolation and purification of taxol and its natural analogues
US5380916A (en) 1990-11-02 1995-01-10 University Of Florida Method for the isolation and purification of taxane derivatives
JPH04185601A (ja) 1990-11-20 1992-07-02 Unitika Ltd 白金抗癌剤徐放性製剤
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US5561136A (en) 1990-12-13 1996-10-01 Merrell Pharmaceuticals Inc. Method of treating cancer by conjunctive therapy with N,N'-bis[ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5272056A (en) 1991-01-03 1993-12-21 The Research Foundation Of State University Of New York Modification of DNA and oligonucleotides using metal complexes of polyaza ligands
HUT68856A (en) 1991-01-11 1995-08-28 Glaxo Lab Sa Acridine derivatives, pharmaceutical compositions comprising the same compouds as effective substances and a process for producing the compounds and the pharmaceutical compositions
US5684168A (en) 1991-01-17 1997-11-04 Rhone-Poulenc Rorer S.A. β-phenylisoserine-(2R,3S), salts, preparation and use thereof
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
TW221441B (zh) 1991-01-25 1994-03-01 Taiho Pharmaceutical Co Ltd
ES2097905T3 (es) 1991-02-25 1997-04-16 Debiopharm Sa Agentes terapeuticos para el tratamiento de la resistencia multidroga de canceres.
US5171217A (en) 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
GB9105037D0 (en) 1991-03-09 1991-04-24 Johnson Matthey Plc Improvements in chemical compounds
US5194635A (en) 1991-03-18 1993-03-16 Virginia Tech Intellectual Properties, Inc. Rearranged taxol compounds and method of using in testing of in vivo activity
EP0586378B1 (en) 1991-03-23 1998-09-23 Sunkyong Industries Ltd. Novel platinum(ii) complex and processes for preparing the same
EP0580759B1 (en) 1991-04-19 1999-05-26 The University Of Mississippi Methods and compositions for isolating taxanes
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
US5407653A (en) 1991-06-26 1995-04-18 Brigham And Women's Hospital Evaluation of the multidrug resistance phenotype
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
FR2678833B1 (fr) 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
FR2678930B1 (fr) 1991-07-10 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii.
US5220016A (en) 1991-07-29 1993-06-15 Board Of Regents, The University Of Texas System Synthesis of navelbine analogs
AU662551B2 (en) 1991-08-09 1995-09-07 Teikoku Hormone Mfg. Co., Ltd. Novel tetrapeptide derivative
CA2096417C (en) 1991-08-22 2000-10-10 Sarah S. Bacus Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
US5571153A (en) 1991-09-20 1996-11-05 Wallst+E,Acu E+Ee N; Hans I. Device for hyperthermia treatment
US6028205A (en) 1991-09-23 2000-02-22 Florida State University C2 tricyclic taxanes
US6018073A (en) 1991-09-23 2000-01-25 Florida State University Tricyclic taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them
US5284864A (en) 1991-09-23 1994-02-08 Florida State University Butenyl substituted taxanes and pharmaceutical compositions containing them
US5710287A (en) 1991-09-23 1998-01-20 Florida State University Taxanes having an amino substituted side-chain and pharmaceutical compositions containing them
US6011056A (en) 1991-09-23 2000-01-04 Florida State University C9 taxane derivatives and pharmaceutical compositions containing them
US5274124A (en) 1991-09-23 1993-12-28 Florida State University Metal alkoxides
US5998656A (en) 1991-09-23 1999-12-07 Florida State University C10 tricyclic taxanes
US5654447A (en) 1991-09-23 1997-08-05 Florida State University Process for the preparation of 10-desacetoxybaccatin III
US5721268A (en) 1991-09-23 1998-02-24 Florida State University C7 taxane derivatives and pharmaceutical compositions containing them
US5229526A (en) 1991-09-23 1993-07-20 Florida State University Metal alkoxides
US5243045A (en) 1991-09-23 1993-09-07 Florida State University Certain alkoxy substituted taxanes and pharmaceutical compositions containing them
US5739362A (en) 1991-09-23 1998-04-14 Florida State University Taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them
US5250683A (en) 1991-09-23 1993-10-05 Florida State University Certain substituted taxanes and pharmaceutical compositions containing them
US5430160A (en) 1991-09-23 1995-07-04 Florida State University Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides
US5399726A (en) 1993-01-29 1995-03-21 Florida State University Process for the preparation of baccatin III analogs bearing new C2 and C4 functional groups
US5227400A (en) 1991-09-23 1993-07-13 Florida State University Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5338872A (en) 1993-01-15 1994-08-16 Florida State University Process for the preparation of 10-desacetoxybaccatin III and 10-desacetoxytaxol and derivatives thereof
US5489601A (en) 1991-09-23 1996-02-06 Florida State University Taxanes having a pyridyl substituted side-chain and pharmaceutical compositions containing them
US6005138A (en) 1991-09-23 1999-12-21 Florida State University Tricyclic taxanes having a butenyl substituted side-chain and pharmaceutical compositions containing them
US5350866A (en) 1991-09-23 1994-09-27 Bristol-Myers Squibb Company 10-desacetoxytaxol derivatives
US5714513A (en) 1991-09-23 1998-02-03 Florida State University C10 taxane derivatives and pharmaceutical compositions
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5728850A (en) 1991-09-23 1998-03-17 Florida State University Taxanes having a butenyl substituted side-chain and pharmaceutical compositions containing them
US5728725A (en) 1991-09-23 1998-03-17 Florida State University C2 taxane derivaties and pharmaceutical compositions containing them
FR2682110B1 (fr) 1991-10-02 1995-05-24 Atta Ligands amphiphiles perfluoroalkyles leurs complexes metalliques et leurs utilisations dans des preparations a usage therapeutique.
US6022541A (en) 1991-10-18 2000-02-08 Beth Israel Deaconess Medical Center Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5344775A (en) 1991-11-15 1994-09-06 Escagenetics Corporation Synthesis of taxanes in culture using pseudocalluscells
ZA928771B (en) 1991-11-15 1993-09-08 Smithkline Beecham Corp Combination chemotherapy
US5738838A (en) 1992-02-20 1998-04-14 Rhomed Incorporated IKVAV peptide radiopharmaceutical applications
US5556609A (en) 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
DE69329304T2 (de) 1992-01-15 2001-01-04 E.R. Squibb & Sons, Inc. Enzymatische Verfahren zur Resolution von Enantiomeren-Mischungen nützlich wie Zwischenprodukte zur Herstellung von Taxanen
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
FR2687145B1 (fr) 1992-02-07 1994-03-25 Rhone Poulenc Rorer Sa Nouveaux anhydrides d'acides, leur preparation et leur emplot et
US5407816A (en) 1992-02-20 1995-04-18 Phyton Catalytic, Inc. Enhanced production of taxol and taxanes by cell cultures of taxus species
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6004554A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
IT1254517B (it) 1992-03-06 1995-09-25 Indena Spa 14-beta idrossi-10-deacetil-baccatina iii, suoi derivati, loro prepazione ed impiego terapeutico
US5698712A (en) 1992-03-06 1997-12-16 Indena S.P.A. Baccatine III derivatives
IT1254515B (it) 1992-03-06 1995-09-25 Indena Spa Tassani di interesse oncologico, loro metodo di preparazione ed uso
FR2688499B1 (fr) 1992-03-10 1994-05-06 Rhone Poulenc Rorer Sa Procede de preparation de la beta-phenylisoserine et de ses analogues.
US5939561A (en) 1992-03-10 1999-08-17 Rhone-Poulence Rorer S.A. Process for the preparation of β-phenylisoserine and β-lactam and their analogues
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
EP0563475B1 (en) * 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US5850032A (en) 1992-04-01 1998-12-15 Union Camp Corporation Method for production of plant biological products in precocious neomorphic embryoids
EP0633719A4 (en) 1992-04-01 1995-12-20 Union Camp Corp PROCESS FOR INDUCING SOMATIC EMBRYOGENESIS IN THE -i (TAXUS) AND PRODUCTION OF ALKALOIDS CONTAINING A TAXANE CORE ACCORDING TO THIS PROCESS.
US5254703A (en) 1992-04-06 1993-10-19 Florida State University Semi-synthesis of taxane derivatives using metal alkoxides and oxazinones
CA2434692A1 (en) 1992-04-07 1993-10-08 Paul M. Cino Callus cell induction and the preparation of taxanes
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US5622960A (en) 1992-04-14 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Topoisomerase II inhibitors and therapeutic uses therefor
US5322779A (en) 1992-04-16 1994-06-21 The Research And Development Institute, Inc. At Montana State University Taxol production by taxomyces andreanae
US5831002A (en) 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
US5237064A (en) 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
DE4317458A1 (de) 1992-06-11 1993-12-16 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung
US5459269A (en) 1992-06-18 1995-10-17 North Carolina State University 14-halo-camptothecins
YU43193A (sh) 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5279953A (en) 1992-06-24 1994-01-18 Esca Genetics Corporation In vivo production of taxanes
CA2120745A1 (en) 1992-06-30 1994-01-06 Philip G. Kasprzyk A combination of anti-erbb-2 monoclonal antibodies and method of using
US5334732A (en) 1992-07-02 1994-08-02 Hauser Chemical Research, Inc. Oxidation of cephalomannine with ozone in the presence of taxol
US5792877A (en) 1992-07-02 1998-08-11 Hauser Chemical Research, Inc. Girard derivatives of taxanes
US5364947A (en) 1992-07-02 1994-11-15 Hauser Chemical Research, Inc. Process for separating cephalomannine from taxol using ozone and water-soluble hydrazines or hydrazides
US5354331A (en) 1992-07-15 1994-10-11 Schachar Ronald A Treatment of presbyopia and other eye disorders
US5391745A (en) 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
US5446047A (en) 1992-07-23 1995-08-29 Sloan-Kettering Institute For Cancer Research Camptothecin analogues
IL102617A (en) 1992-07-23 1996-01-19 Technion Res & Dev Foundation Method for Assessing Clinical Sensitivity and Multidrug Resistance to Mammalian Cell Anticancer Compounds
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5256801A (en) 1992-08-14 1993-10-26 Napro Biotherapeutics, Inc. Processes of converting taxanes into 10-deacetylbaccatin III
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
US5470866A (en) 1992-08-18 1995-11-28 Virginia Polytechnic Institute And State University Method for the conversion of cephalomannine to taxol and for the preparation of n-acyl analogs of taxol
US5871710A (en) 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696459B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696460B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696454B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation stéréosélective d'un dérivé de la beta-phénylisosérine et son utilisation pour la préparation de dérivés du Taxane.
US5817321A (en) 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
US5411984A (en) 1992-10-16 1995-05-02 Virginia Tech Intellectual Properties, Inc. Water soluble analogs and prodrugs of taxol
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
GB9222253D0 (en) 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
US5891724A (en) 1992-10-27 1999-04-06 Queen's University At Kingston Methods for conferring multidrug resistance on a cell
FR2697522B1 (fr) 1992-10-30 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
US5356928A (en) 1992-11-06 1994-10-18 Hauser Chemical Research, Inc. Cytotoxic agents
US5412116A (en) 1992-11-06 1995-05-02 Hauser Chemical Research, Inc. Oxidation of glycoside substituted taxanes to taxol or taxol precursors and new taxane compounds formed as intermediates
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5420337A (en) 1992-11-12 1995-05-30 E. R. Squibb & Sons, Inc. Enzymatic reduction method for the preparation of compounds useful for preparing taxanes
AP9300587A0 (en) 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
FR2698363B1 (fr) 1992-11-23 1994-12-30 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions qui les contiennent.
US5281727A (en) 1992-11-27 1994-01-25 Napro Biotherapeutics, Inc. Method of using ion exchange media to increase taxane yields
WO1994012268A1 (en) 1992-11-27 1994-06-09 Napro Biotherapeutics, Inc. Processing taxane solutes using membranes
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
CA2126698A1 (en) 1992-12-07 1994-06-23 Muraleedharan G. Nair Process for the isolation and purification of taxol and taxanes from taxus spp.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5814658A (en) 1992-12-09 1998-09-29 Rhone-Poulenc Rorer S.A. Taxoids, their preparation and pharmaceutical compositions containing them
WO1994013695A1 (en) 1992-12-16 1994-06-23 Basf Aktiengesellschaft Dolostatin analog
FR2699535B1 (fr) 1992-12-22 1995-03-17 Pf Medicament Dérivés de l'étoposide, leur procédé de préparation, leur utilisation à titre de médicament et leur utilisation pour la préparation d'un médicament destiné au traitement anticancéreux.
US5973160A (en) 1992-12-23 1999-10-26 Poss; Michael A. Methods for the preparation of novel sidechain-bearing taxanes
US5622977A (en) 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9226830D0 (en) 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5646176A (en) 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
US5352804A (en) 1993-01-19 1994-10-04 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 2
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
ATE253563T1 (de) 1993-02-05 2003-11-15 Bryn Mawr College Synthese von taxol, seinen analogen und intermediaten mit variablen a-ring seitenketten
DE4305003A1 (de) 1993-02-18 1994-08-25 Knoll Ag Verfahren zur Herstellung kolloidaler wäßriger Lösungen schwer löslicher Wirkstoffe
US5527913A (en) 1993-02-25 1996-06-18 The Stehlin Foundation For Cancer Research Methods for purifying camptothecin compounds
US5604112A (en) 1993-02-26 1997-02-18 The Dupont Merck Pharmaceutical Company Method for detecting the cardiotoxicity of compounds
US5844001A (en) 1993-02-26 1998-12-01 Research Development Foundation Combination platinum chemotherapeutic/antiestrogen therapy for human cancers
US5756301A (en) 1993-03-03 1998-05-26 The Trustees Of Columbia University In The City Of New York Endogenous taxol-like substance in human serum, monoclonal antibodies directed thereto and methods of assaying therefor
ES2193154T3 (es) 1993-03-05 2003-11-01 Univ Florida State Procedimiento para la preparacion de 9-desoxotaxanos.
US5547981A (en) 1993-03-09 1996-08-20 Enzon, Inc. Taxol-7-carbazates
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5703247A (en) 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
US5824664A (en) 1993-03-26 1998-10-20 U.S. Bioscience, Inc. Suppression of HIV expression by organic thiophosphate
US5475011A (en) 1993-03-26 1995-12-12 The Research Foundation Of State University Of New York Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment
FR2703353B1 (fr) 1993-03-29 1995-05-05 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés de la beta-phénylisosérine.
WO1994022478A1 (en) 1993-03-30 1994-10-13 The Trustees Of The University Of Pennsylvania PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
US5482698A (en) 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
US5336684A (en) 1993-04-26 1994-08-09 Hauser Chemical Research, Inc. Oxidation products of cephalomannine
AU6833994A (en) 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
CA2163107C (en) 1993-05-17 2001-04-17 David Milton Goldenberg Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
IT1261667B (it) 1993-05-20 1996-05-29 Tassano ad attivita' antitumorale.
US5380897A (en) 1993-05-25 1995-01-10 Hoeschele; James D. Tri(platinum) complexes
US5405963A (en) 1993-06-10 1995-04-11 Smithkline Beecham Corporation Process for asymmetric total synthesis of camptothecin analogues
PT703909E (pt) 1993-06-11 2000-10-31 Upjohn Co Utilizacao de delta-6,7-taxois antineoplasticos e composicoes farmaceuticas que os contem
US5516676A (en) 1993-06-15 1996-05-14 Bristol-Myers Squibb Company Preparation of C-13 hydroxyl-bearing taxanes using nocardioides or a hydrolase isolated therefrom
US5523219A (en) 1993-06-15 1996-06-04 Bristol-Myers Squibb Company Enzymatic hydrolysis method for the preparation of C-10 hydroxyl-bearing taxanes and enzymatic esterification method for the preparation of C-10 acyloxy-bearing
US5409690A (en) 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
US5744605A (en) 1993-06-30 1998-04-28 University Of Pittsburgh Intermediates in the synthesis of (+) camptothecin and related compounds and synthesis thereof
TW397866B (en) 1993-07-14 2000-07-11 Bristol Myers Squibb Co Enzymatic processes for the resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5405972A (en) 1993-07-20 1995-04-11 Florida State University Synthetic process for the preparation of taxol and other tricyclic and tetracyclic taxanes
US6005120A (en) 1993-07-20 1999-12-21 Florida State University Tricyclic and tetracyclic taxanes
JP3161490B2 (ja) 1993-07-30 2001-04-25 松下電器産業株式会社 金型装置
US5455270A (en) 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
US5409677A (en) 1993-08-26 1995-04-25 The Curators Of The University Of Missouri Process for separating a radionuclide from solution
US5475108A (en) 1993-08-31 1995-12-12 North Carolina State University Camptothecin intermediates and method of making camptothecin and comptothecin analogs
US5409915A (en) 1993-09-14 1995-04-25 The University Of Vermont And State Agricultural College Bis-platinum (IV) complexes as chemotherapeutic agents
US5498227A (en) 1993-09-15 1996-03-12 Mawad; Michel E. Retrievable, shielded radiotherapy implant
US5484612A (en) 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
GB9319944D0 (en) 1993-09-28 1993-11-17 Erba Carlo Spa Process for the preparation of 9-amino camptothecin
ES2233928T3 (es) 1993-10-01 2005-06-16 Teikoku Hormone Mfg. Co., Ltd. Derivados de dolastatina.
EP0646589A3 (en) 1993-10-04 1995-06-28 Tanaka Precious Metal Ind Anti-tumor platinum (IV) complexes.
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
KR970010594B1 (ko) 1993-10-16 1997-06-28 한국과학기술연구원 말론산 유도체의 백금착화합물 및 그 제조방법
JPH09504033A (ja) 1993-10-20 1997-04-22 エンゾン，インコーポレーテッド ２’−及び／又は７−置換タキソイド類
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
CA2172824A1 (en) 1993-10-25 1995-05-04 Charles M. Moehle Methods for screening for antimycotics
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5459248A (en) 1993-11-04 1995-10-17 Bristol-Myers Squibb Company Process of preparing etoposide phosphate and etoposide
US5633177A (en) 1993-11-08 1997-05-27 Advanced Micro Devices, Inc. Method for producing a semiconductor gate conductor having an impurity migration barrier
US5821453A (en) 1993-11-12 1998-10-13 The Ohio State University Research Foundation Molecular based magnets comprising vanadium tetracyanoethylene complexes for shielding electromagnetic fields
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
DE69431135T2 (de) 1993-11-15 2003-03-27 Mitsui Chemicals, Inc. Methode zur Herstellung von Taxan-Typ Diterpen und Methode zur Gewinnung von Kulturzellen die Taxan-Typ Diterpen in hohen Ausbeuten herstellen
US5436243A (en) 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5855748A (en) 1993-11-22 1999-01-05 E. I. Du Pont De Nemours And Company Electrochemical cell having a mass flow field made of glassy carbon
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
CA2179490A1 (en) 1993-12-21 1995-06-29 Trimurtulu Golakoti New cryptophycins
US5955423A (en) 1993-12-21 1999-09-21 The University Of Hawaii Cryptophycins
US5952298A (en) 1993-12-21 1999-09-14 The University Of Hawaii Cryptophycins
EP0738268B1 (en) 1993-12-22 2004-03-03 Celltech R&D Limited Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
GB9326173D0 (en) 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
US5447936A (en) 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5476939A (en) 1993-12-30 1995-12-19 Abbott Laboratories Certain pyridyl and isoquinolyl carbinolamine derivatives
IL112061A (en) 1994-01-13 1999-10-28 Bristol Myers Squibb Co Methods for the preparation of taxanes
US5491285A (en) 1994-01-21 1996-02-13 Goldsmith Seeds Inc. Phytophthora resistance gene of catharanthus and its use
IL127599A (en) 1994-01-28 2004-06-01 Upjohn Co Process for preparing isotaxol analogs
AT400950B (de) 1994-02-04 1996-04-25 Immodal Pharmaka Gmbh Verfahren zur technischen herstellung definierter isomerengemische aus verbindungen mit spirozyklischen - aminocarboxyl- und/oder spirozyklischen - aminocarbonyl-systemen
GB9402934D0 (en) 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
US5565478A (en) 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
FR2718135B1 (fr) 1994-04-05 1996-04-26 Rhone Poulenc Rorer Sa Procédé de préparation d'hydroxy-7 taxanes.
US5449790A (en) 1994-04-06 1995-09-12 Hauser Chemical Research, Inc. Preparation of 10-deacetylbaccatin III and 7-protected-10-deacetylbaccatin III derivatives from 10-deacetyl taxol A, 10-deacetyl taxol B, and 10-deacetyl taxol C
US5646011A (en) 1994-04-08 1997-07-08 Yokoyama; Shiro Cisplatin resistance gene and uses therefor
DE4415263C1 (de) 1994-04-15 1995-11-30 Asta Medica Ag Cis-[trans-1,2-Cyclobutanbis(methylamin)-N,N']-[(2S)-lactato-O·1·, O·2·]-platin(II)-trihydrat (Lobaplatin-Trihydrat), seine Herstellung und arzneiliche Verwendung
CA2164519A1 (en) 1994-04-19 1995-10-26 Hideki Kawai Novel platinum (ii) complex and remedy for malignant tumor
US5468754A (en) 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
GB9408218D0 (en) 1994-04-26 1994-06-15 Johnson Matthey Plc Improvements in platinum complexes
US5604233A (en) 1994-04-28 1997-02-18 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
US5597829A (en) 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5882941A (en) 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
IT1269634B (it) 1994-05-06 1997-04-08 Indena Spa Medicamento topico ad attivita' cicatrizzante
DE4415998A1 (de) 1994-05-06 1995-11-09 Basf Ag Neue Tetrapeptide, ihre Herstellung Verwendung
JP4221515B2 (ja) 1994-05-23 2009-02-12 セファロン リミテッド 製剤調製機
GB9410388D0 (en) 1994-05-24 1994-07-13 Erba Carlo Spa Method for the preparation of 9-amino camptothecin
US5508447A (en) 1994-05-24 1996-04-16 Board Of Regents, The University Of Texas System Short synthetic route to taxol and taxol derivatives
US5632982A (en) 1994-06-07 1997-05-27 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic enhancement of TNF with copper
US5605826A (en) 1994-06-10 1997-02-25 Panorama Research, Inc. 24 kilodalton cytoplasmic protease activating DNA fragmentation in apoptosis
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US5602272A (en) 1994-06-21 1997-02-11 Bristol-Myers Squibb Company Reduction and resolution methods for the preparation of compounds useful as intemediates for preparing taxanes
US5563132A (en) 1994-06-21 1996-10-08 Bodaness; Richard S. Two-step cancer treatment method
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5714163A (en) 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5648505A (en) 1994-06-28 1997-07-15 Xia; Zhi-Qiang Method for the preparation of a novel C-ring precursor for taxoids and novel intermediates
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US5498738A (en) 1994-06-28 1996-03-12 Karvinen; Esko Method for the preparation of a novel a-ring precursor for taxoids and novel intermediates
US5786344A (en) 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5864024A (en) 1994-07-11 1999-01-26 Glinskii; Guennadi Victor Synthetic glycoamines and methods for their use that affect cell adhesion, inhibit cancer cell metastasis, and induce apoptosis
US5629433A (en) 1994-07-18 1997-05-13 Hauser, Inc. Selective process for the deacylation and deacetylation of taxol and taxanes
US5616330A (en) 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
US5646159A (en) 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
US5547866A (en) 1994-07-20 1996-08-20 The Regents Of The University Of California Taxane production in haploid-derived cell cultures
US5561042A (en) 1994-07-22 1996-10-01 Cancer Therapy And Research Center Diamine platinum naphthalimide complexes as antitumor agents
US5763477A (en) 1994-07-22 1998-06-09 Dr. Reddy's Research Foundation Taxane derivatives from 14-β-hydroxy-10 deacetylbaccatin III
US5604095A (en) 1994-07-22 1997-02-18 Cancer Therapy & Research Center Unsymmetrically linked bisnaphthalimides as antitumor agents
SK281526B6 (sk) 1994-07-26 2001-04-09 Indena S. P. A. Semisyntetický taxán, spôsob jeho prípravy a medziprodukt, semisyntetický sekotaxán, spôsob jeho prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
NZ291368A (en) 1994-08-19 1999-04-29 Wallone Region A compound comprising a marker or a therapeutic agent linked to a ligand containing amino acids wherein the marker or agent is cleaved from the ligand to permit entry into the cell of the marker or agent, medicaments for treating tumours; diagnostic devices
US5479648A (en) * 1994-08-30 1995-12-26 Stratus Computer, Inc. Method and apparatus for switching clock signals in a fault-tolerant computer system
JPH0873461A (ja) 1994-09-06 1996-03-19 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体、その製造法および抗腫瘍剤
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
FR2725990B1 (fr) 1994-10-21 1997-01-10 Pf Medicament Derives hydrosolubles d'epipodophyllotoxine, leur procede de preparation, leur utilisation a titre de medicament, et leur utilisation destinee aux traitements anticancereux
JPH09509431A (ja) 1994-11-04 1997-09-22 フアルマシア・エツセ・ピー・アー タキサン誘導体
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
DE4440193A1 (de) 1994-11-10 1996-05-15 Bayer Ag Verwendung von Dioxomorpholinen zur Bekämpfung von Endoparasiten, neue Dioxomorpholine und Verfahren zur ihrer Herstellung
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5789000A (en) 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
CA2162086A1 (en) 1994-11-15 1996-05-16 Michihito Ise Agent for reducing nephrotoxicity due to medicine
US5783178A (en) 1994-11-18 1998-07-21 Supratek Pharma. Inc. Polymer linked biological agents
RU2182598C2 (ru) 1994-11-21 2002-05-20 Новартис Аг Модифицированные ингибиторы протеиназы
US5679648A (en) * 1994-11-30 1997-10-21 The University Hospital Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5654328A (en) 1994-12-15 1997-08-05 Sredni; Benjamin Method and composition for reducing tumor development with a combination of platinum and tellurium or selenium compounds
US5597830A (en) 1994-12-20 1997-01-28 Warner-Lambert Company Combination chemotherapy
GB9426090D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5580899A (en) 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US5679807A (en) 1995-01-30 1997-10-21 Hauser, Inc. Preparation of taxol and docetaxel through primary amines
US5496952A (en) 1995-02-07 1996-03-05 North Carolina State University Method of making asymmetric DE ring intermediates for the synthesis of camptothecin and camptothecin analogs
GB9502799D0 (en) 1995-02-14 1995-04-05 Johnson Matthey Plc Improvements in platinum complexes
US5620875A (en) 1995-02-17 1997-04-15 University Of Portland Transfer of taxol from yew tree cuttings into a culture medium over time
US5547982A (en) 1995-02-27 1996-08-20 Johnson Matthey, Inc. Anti-tumor platinum complexes
JPH11501931A (ja) 1995-03-10 1999-02-16 ハウザー，インコーポレイテッド セファロマンニンエポキシド、その類似体およびそれらの製造方法
IT1275936B1 (it) 1995-03-17 1997-10-24 Indena Spa Derivati della 10-deacetilbaccatina iii e della 10-deacetil-14b- idrossibaccatina iii loro metodo di preparazione e formulazioni
US5736156A (en) 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
WO1996030056A1 (en) 1995-03-29 1996-10-03 The Curators Of The University Of Missouri Hydroxyalkyl phosphine compounds for use as diagnostic and therapeutic pharmaceuticals and method of making same
US5855867A (en) 1995-03-29 1999-01-05 The Curators Of The University Of Missouri Hydroxymethyl phosphine compounds for use as diagnostic and therapeutic pharmaceuticals and method of making same
TW438775B (en) 1995-04-07 2001-06-07 Pharmacia & Upjohn Co Llc Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
US5840929A (en) 1995-04-14 1998-11-24 Bristol-Myers Squibb Company C4 methoxy ether derivatives of paclitaxel
DK0831100T3 (da) 1995-04-21 2001-01-02 Teikoku Hormone Mfg Co Ltd Nye peptidderivater
US5677286A (en) 1995-04-27 1997-10-14 The University Of Michigan Glycosylated analogs of camptothecin
US5900367A (en) 1995-04-29 1999-05-04 Samyang Genex Co., Ltd. Method for purifying taxol from taxus biomass
US5834012A (en) 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
US5561055A (en) 1995-05-05 1996-10-01 Bcm Developpement Inc. Bacterial mass production of taxanes with Erwinia
US5767142A (en) 1996-03-20 1998-06-16 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
US5807874A (en) 1995-05-17 1998-09-15 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
GB9510716D0 (en) 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5670500A (en) 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5595878A (en) 1995-06-02 1997-01-21 Boron Biologicals, Inc. Detection of biopolymers and biooligomers with boron hydride labels
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5935967A (en) 1995-06-05 1999-08-10 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of highly lipophilic camptothecin derivatives
US5972955A (en) 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin
EP0846107A1 (en) 1995-06-06 1998-06-10 Pharmeco Laboratories, Inc. Stereoselective method for synthesizing dolaphenine
US5780653A (en) 1995-06-07 1998-07-14 Vivorx Pharmaceuticals, Inc. Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
WO1997000271A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
GB9512471D0 (en) 1995-06-20 1995-08-23 Pharmacia Spa Method for the preparation of taxol and its derivatives
GB9512670D0 (en) 1995-06-21 1995-08-23 Sod Conseils Rech Applic Camptothecin analogues
SI2275119T1 (sl) 1995-07-27 2013-12-31 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
DE19527574A1 (de) 1995-07-28 1997-01-30 Basf Ag Verfahren zur Herstellung vona-(N,N-Dialkyl)-aminocaarbonsäureamiden
DE19527575A1 (de) 1995-07-28 1997-01-30 Basf Ag Verfahren zur Herstellung von peptidischer Wirkstoffe
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
US5760251A (en) 1995-08-11 1998-06-02 Sepracor, Inc. Taxol process and compounds
EP0850316A4 (en) 1995-08-30 2000-08-23 Univ Hawaii CRYPTOPHYCINS OBTAINED FROM AN ABERRANT BIOSYNTHESIS
DK1229030T3 (da) 1995-09-12 2006-02-13 Zeneus Pharma Ltd Hydrolysefremmende, hydrofobe taxanderivater
US6107332A (en) 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
US6051600A (en) 1995-09-12 2000-04-18 Mayhew; Eric Liposomal hydrolysis-promoting hydrophobic taxane derivatives
US5753507A (en) 1995-09-22 1998-05-19 Novartis Finance Corporation Plant geraniol/nerol 10-hydroxylase and DNA coding therefor
KR0164460B1 (ko) 1995-10-02 1999-03-20 김은영 고분자 백금 착화합물, 그의 제조방법 및 그를 유효성분으로 하는 항암제
US5654448A (en) 1995-10-02 1997-08-05 Xechem International, Inc. Isolation and purification of paclitaxel from organic matter containing paclitaxel, cephalomannine and other related taxanes
US5840748A (en) 1995-10-02 1998-11-24 Xechem International, Inc. Dihalocephalomannine and methods of use therefor
US5854278A (en) 1995-12-13 1998-12-29 Xechem International, Inc. Preparation of chlorinated paclitaxel analogues and use thereof as antitumor agents
US5807888A (en) 1995-12-13 1998-09-15 Xechem International, Inc. Preparation of brominated paclitaxel analogues and their use as effective antitumor agents
JP2907781B2 (ja) 1995-11-06 1999-06-21 エフ・ホフマン−ラ ロシユ アーゲー （４，５）−トランス−オキサゾリジンの新規製造法
US5807984A (en) 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
US6288237B1 (en) 1995-11-17 2001-09-11 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
US5849790A (en) 1995-11-17 1998-12-15 The University Of South Florida (Mono) ethylenediaminenitroplatinum (IV) complexes with ligands of oxides of nitrogen as possible anti-tumor agents
AU7732996A (en) 1995-11-22 1997-06-11 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
IL119749A (en) 1995-12-04 2001-03-19 Nippon Kayaku Kk Process for producing etoposide
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
AU1469097A (en) 1995-12-22 1997-07-17 Eli Lilly And Company Pharmaceutical compounds
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
GB9600438D0 (en) 1996-01-10 1996-03-13 Pharmacia Spa Hexacyclic camptothecin analogues, and process for preparing them
US5776925A (en) 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
US5731316A (en) 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US6096336A (en) 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
GB9601779D0 (en) 1996-01-30 1996-04-03 Pharmacia Spa 9, 10 Disubstituted camptothecin derivatives
US5670663A (en) 1996-02-14 1997-09-23 Regents Of The University Of California Recovery of taxanes from conifers
JP2000507215A (ja) 1996-02-21 2000-06-13 マトリックス ファーマシューティカルズ インコーポレイテッド 細胞増殖系疾患の治療の際の細胞膜透過剤の使用
DE69704731D1 (de) 1996-02-27 2001-06-13 Lilly Co Eli Cryptophycinderivate und ihre Verwendung als antimikrotubuli Mittel
US5710099A (en) 1996-02-27 1998-01-20 The United States Of America As Represented By The Secretary Of Agriculture Bioactive compounds
AU735900B2 (en) 1996-03-12 2001-07-19 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
IT1283633B1 (it) 1996-05-10 1998-04-23 Indena Spa Derivati tassanici loro sintesi e formulazioni che li contengono
IT1283635B1 (it) 1996-05-10 1998-04-23 Indena Spa Composti a scheletro camptotecinico isolati da mappia foetida e loro uso come sintoni per farmaci o come principi attivi
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5968517A (en) 1996-05-23 1999-10-19 Duncan; Kelvin Winston Process for extraction of proanthocyanidins from botanical material
US5883120A (en) 1997-06-16 1999-03-16 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Antifungal activity of the spongistatins
US5877205A (en) 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
US5635531A (en) 1996-07-08 1997-06-03 Bristol-Myers Squibb Company 3'-aminocarbonyloxy paclitaxels
US5780446A (en) 1996-07-09 1998-07-14 Baylor College Of Medicine Formulations of vesicant drugs and methods of use thereof
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
CA2259977C (en) 1996-07-15 2005-06-28 Kabushiki Kaisha Yakult Honsha Taxane derivatives and drugs containing the same
US5741892A (en) 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
US5939527A (en) 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents
WO1998007727A1 (en) 1996-08-19 1998-02-26 Bionumerik Pharmaceuticals, Inc. Highly lipophilic camptothecin derivatives
WO1998008833A1 (en) 1996-08-26 1998-03-05 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
US5969145A (en) 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
WO1998008829A1 (en) 1996-08-30 1998-03-05 Eli Lilly And Company Pharmaceutical compounds
JP2001502297A (ja) 1996-08-30 2001-02-20 イーライ・リリー・アンド・カンパニー 医薬用化合物
WO1998008505A1 (en) 1996-08-30 1998-03-05 Eli Lilly And Company Pharmaceutical compounds
EP0932601A4 (en) 1996-08-30 2000-02-02 Lilly Co Eli METHOD FOR PRODUCING PHARMACEUTICALS
JP4849700B2 (ja) * 1996-09-03 2012-01-11 中外製薬株式会社 抗インテグリンα３抗体の複合体
CA2264557A1 (en) 1996-09-06 1998-03-12 Eli Lilly And Company Process and novel intermediates
CA2264245A1 (en) 1996-09-06 1998-03-12 Eli Lilly And Company Process to prepare pharmaceutical compounds
EP0929535A4 (en) 1996-09-06 2001-05-23 Lilly Co Eli PROCESS AND NEW INTERMEDIATE PRODUCTS
HUP0000212A3 (en) 1996-09-06 2001-12-28 Wayne State University Detroit Process to prepare cryptophycin derivatives and intermediates thereof
US20020052309A1 (en) 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
US5773464A (en) 1996-09-30 1998-06-30 Bristol-Myers Squibb Company C-10 epoxy taxanes
KR20060079258A (ko) 1996-10-18 2006-07-05 제넨테크, 인크. 항-ＥｒｂＢ２ 항체
US5832931A (en) 1996-10-30 1998-11-10 Photogen, Inc. Method for improved selectivity in photo-activation and detection of molecular diagnostic agents
US5829448A (en) 1996-10-30 1998-11-03 Photogen, Inc. Method for improved selectivity in photo-activation of molecular agents
CN1196698C (zh) 1996-11-18 2005-04-13 生物技术研究有限公司(Gbf) Epothilone D、E和F,其制备方法,以及作为细胞抑制剂和植物保护剂的应用
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
GB9625184D0 (en) 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
US5843475A (en) 1996-12-06 1998-12-01 Board Of Regents, The University Of Texas System Delivery and activation through liposome incorporation of diaminocyclohexane platinum (II) complexes
CA2274641A1 (en) 1996-12-12 1998-06-18 David Richard Corbin Improved packaging composition
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
BR9714266A (pt) 1997-01-06 2000-04-18 Pfizer Derivados de sulfona cìclicos.
US5833994A (en) 1997-01-08 1998-11-10 Paracelsian, Inc. Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
US5910102A (en) 1997-01-10 1999-06-08 Scimed Life Systems, Inc. Conversion of beta radiation to gamma radiation for intravascular radiation therapy
US5739359A (en) 1997-01-24 1998-04-14 Virginia Tech Intellectual Properties, Inc. Methods for preparing 1-deoxy paclitaxels
CA2281105A1 (en) 1997-02-25 1998-09-03 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilones with a modified side chain
EP0975610A4 (en) 1997-02-26 2000-05-17 Lilly Co Eli PHARMACEUTICAL COMPOUNDS BASED ON TRIPEPTIDES AND TETRAPEPTIDES
NZ336918A (en) 1997-02-26 2001-11-30 Lilly Co Eli Selective epoxidation process for preparing pharmaceutical compounds comprising Cryptophycin 52
US5902822A (en) 1997-02-28 1999-05-11 Bristol-Myers Squibb Company 7-methylthiooxomethyl and 7-methylthiodioxomethyl paclitaxels
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
US5886025A (en) 1997-03-06 1999-03-23 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US5994367A (en) 1997-03-07 1999-11-30 The University Of North Carolina At Chapel Hill Method for treating tumors using 2-aryl-naphthyridin-4-ones
US5965537A (en) 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US5939455A (en) 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
GB9705035D0 (en) 1997-03-11 1997-04-30 Pharmacia & Upjohn Spa Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US5843993A (en) 1997-03-14 1998-12-01 The Curators Of The University Of Missouri Hydroxyalkyl phosphine gold complexes for use as diagnostic and therapeutic pharmaceuticals and method of making same
EP0870506A1 (en) 1997-04-11 1998-10-14 Eli Lilly And Company Compositions comprising a cryptophycin compound in combination with a synchronizing or activating agent for treating cancer
EP0870510A3 (en) 1997-04-11 1999-09-15 Eli Lilly And Company Synergistic combination comprising cryptophycin derivatives and microtubule synergizing agents
EP0870501A1 (en) 1997-04-11 1998-10-14 Eli Lilly And Company Use of specific cryptophycin derivatives for the manufacture of a medicament in the treatment of fungal infections
US6017935A (en) 1997-04-24 2000-01-25 Bristol-Myers Squibb Company 7-sulfur substituted paclitaxels
US6117659A (en) 1997-04-30 2000-09-12 Kosan Biosciences, Inc. Recombinant narbonolide polyketide synthase
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6046209A (en) 1997-05-27 2000-04-04 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5919126A (en) 1997-07-07 1999-07-06 Implant Sciences Corporation Coronary stent with a radioactive, radiopaque coating
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
WO1999003848A1 (de) 1997-07-16 1999-01-28 Schering Aktiengesellschaft Thiazolderivate, verfahren zur herstellung und verwendung
GB9715821D0 (en) 1997-07-25 1997-10-01 Pharmacia & Upjohn Spa Amidino-camptothecin derivatives
US5922877A (en) 1997-08-05 1999-07-13 The Stehlin Foundation For Cancer Research Methods of preparing and purifying 9-nitro-20-camptothecin
ATE368036T1 (de) 1997-08-09 2007-08-15 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
US6121278A (en) 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6120800A (en) 1997-09-25 2000-09-19 Nexstar Pharmaceuticals, Inc. Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5917062A (en) 1997-11-21 1999-06-29 Indena S.P.A Intermediates and methods useful in the semisynthesis of paclitaxel and analogs
AU738576B2 (en) 1997-12-04 2001-09-20 Bristol-Myers Squibb Company A process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6020495A (en) 1997-12-08 2000-02-01 Pharm-Eco Laboratories, Inc. Stereoselective method for synthesizing dolaphenine
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6030818A (en) 1997-12-22 2000-02-29 Bcm Developpement, Inc. Bacterial mass production of taxanes and paclitaxel
KR100246722B1 (ko) 1997-12-30 2000-04-01 박호군 경구용 백금 착화합물 항암제 및 그 제조방법
IL137351A0 (en) 1998-02-12 2001-07-24 Univ Rutgers Heterocyclic topoisomerase poisons
US6017890A (en) 1998-02-19 2000-01-25 Ortho-Mcneil Pharmaceutical, Inc. Azole peptidomimetics as thrombin receptor antagonists
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
US6066749A (en) 1998-05-01 2000-05-23 Napro Biotherapeutics, Inc. Method for conversion of C-2'-O-protected-10-hydroxy taxol to c-2'-O-protected taxol:useful intermediates in paclitaxel synthesis
US6048990A (en) 1998-05-01 2000-04-11 Napro Biotherapeutics, Inc. Method for selective acylation of C-2'-O-protected-10-hydroxy-taxol at the C-10 position
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
US5981564A (en) 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
US5985837A (en) 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
AU5963699A (en) 1998-10-02 2000-04-26 Mcmaster University Spliced form of (erb)b-2/neu oncogene
US6025516A (en) 1998-10-14 2000-02-15 Chiragene, Inc. Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes
US6103913A (en) 1998-10-16 2000-08-15 Eli Lilly And Company Process for preparing enollactone derivatives
US6040330A (en) 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
BRPI0009448B8 (pt) 1999-04-01 2021-05-25 Univ Texas kit para uso no tratamento de uma neoplasia em um mamífero
BR0010017A (pt) 1999-04-28 2002-06-11 Univ Texas Composições e processos para o tratamento de câncer por inibição seletiva de vegf
DK1187632T3 (da) 1999-05-14 2009-04-06 Genentech Inc Behandling med anti-ErbB2-antistoffer
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
PT2283866E (pt) 1999-06-25 2015-07-20 Genentech Inc Métodos de tratamento utilizando conjugados de anticorpo anti-erbb-maitansinóide
PT1189641E (pt) 1999-06-25 2009-11-04 Genentech Inc Anticorpos anti-erbb2 humanizados e tratamento com anticorpos anti-erbb2
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
IL147017A0 (en) 1999-06-25 2002-08-14 Genentech Inc TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
US6362342B1 (en) 1999-06-29 2002-03-26 Lion Bioscience Ag Triazole compounds and methods of making same
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
NZ517150A (en) 1999-08-27 2005-01-28 Genentech Inc Dosages for treatment with anti-ErbB2 antibodies
US7030231B1 (en) 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
CA2388063C (en) 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
KR20030029847A (ko) 2000-08-24 2003-04-16 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
EP1992643A3 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20080085283A1 (en) 2001-09-05 2008-04-10 Levinson Arthur D Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US20040235068A1 (en) 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
ATE486092T1 (de) 2001-09-18 2010-11-15 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
US20050238650A1 (en) 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
AU2003247762B2 (en) 2002-07-03 2008-05-01 Immunogen, Inc. Antibodies to non-shed MUC1 and MUC16, and uses thereof
AU2003259913A1 (en) 2002-08-19 2004-03-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CN1816356A (zh) 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7754441B2 (en) 2003-11-17 2010-07-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
JP3991983B2 (ja) 2003-12-19 2007-10-17 日産自動車株式会社 車両の駆動制御装置
EP1696963A2 (en) 2003-12-24 2006-09-06 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체

Also Published As

Publication number Publication date
EP1229934B1 (en) 2014-03-05
EP2266607A2 (en) 2010-12-29
USRE43899E1 (en) 2013-01-01
EP2289549A2 (en) 2011-03-02
WO2001024763A2 (en) 2001-04-12
CA2385528A1 (en) 2001-04-12
JP2008074863A (ja) 2008-04-03
JP4776843B2 (ja) 2011-09-21
HK1049787A1 (zh) 2003-05-30
USRE44704E1 (en) 2014-01-14
JP2003528034A (ja) 2003-09-24
AU7988500A (en) 2001-05-10
AU775373B2 (en) 2004-07-29
WO2001024763A3 (en) 2001-10-11
EP2289549A3 (en) 2011-06-15
EP1229934A2 (en) 2002-08-14
JP5530060B2 (ja) 2014-06-25
US20060233811A1 (en) 2006-10-19
EP2266607A3 (en) 2011-04-20
JP2011148826A (ja) 2011-08-04
EP1229934A4 (en) 2004-11-24
CA2385528C (en) 2013-12-10
US7601354B2 (en) 2009-10-13

Similar Documents

Publication Publication Date Title
EP1229934A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER BY MEANS OF IMMUNO-CONJUGATES AND CHEMOTHERAPEUTIC AGENTS
HUP0201436A2 (en) Methods and compositions for treating solid tumors
AU4768301A (en) Synergistic methods and compositions for treating cancer
AU6147401A (en) Compositions and methods for the treatment of cancer
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
PL352931A1 (en) Compositions and uses of et743 for treating cancer
EP1164848A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING SEXUAL FUNCTIONAL FAULTS
HUP0300848A3 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
IL136167A0 (en) Conjugates useful in the treatment of prostate cancer
IL143212A0 (en) Compositions and methods for the treatment of tumor
IL141426A0 (en) Compositions and methods for the treatment of tumor
EP1161255A4 (en) METHOD AND MEANS FOR TREATING ERECTILE DYSFUNCTION
IL134592A0 (en) Compositions comprising camptothecin compounds for the treatment of cancer with reduced side effects
EG22346A (en) Process for the preparation of conjugates useful in the treatment of prostate cancer
AU2001278738A1 (en) Medicinal compositions for preventing and treating cancer
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
PL352681A1 (en) Preventive and therapeutic agents for cancer
AU5097099A (en) Methods and compositions for cancer treatment
GB9804361D0 (en) Cancer treatment
AU2002360454A8 (en) Methods and compositions for treating cancer
GB9903035D0 (en) Treating cancer
KR100511819B1 (en) Compositions and Methods for the Treatment of Tumor
GB2334579B (en) Treating cancer
GB0021287D0 (en) Composition and method for the treatment of cancers

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170929